Skip to main content

Prenetics Global Ltd

corporate_fare Company Profile

Prenetics Global Ltd

PRE·NASDAQ·Life Sciences·CIK 0001876431

Prenetics Global Ltd is a consumer health company focused on advancing human health and longevity through science-backed products, global brand partnerships, and AI-driven operations. The company's business is organized around two brands: IM8 and CircleDNA. IM8, co-founded with David Beckham, is the flagship consumer health brand and generated $60.1 million in revenue in its first full fiscal year (FY2025), achieving $120 million in Annual Recurring Revenue (ARR) as of December 2025. IM8 ships to more than 30 countries and had a gross margin of approximately 63% in FY2025. This brand was developed to combine clinical-grade formulation with a consumer-grade brand experience. CircleDNA is a retained, complementary asset that generated $12.9 million in revenue in FY2025 with a gross margin of approximately 85%. In FY2025, Prenetics Global Ltd's total revenue from continuing operations was $92.4 million, with a gross profit of $48.8 million and a gross margin of 52.8%. The company reported a loss for the year of $(40.0) million and an Adjusted EBITDA Loss of $(13.9) million in FY2025. In Q4 2025, total revenue reached $36.6 million. IM8 operating metrics for Q4 2025 included monthly revenue of $10.0 million, quarterly revenue of $27.4 million, over 230,000 total customer orders, an average order value of $133, and a new customer subscription rate of approximately 80%.

Prenetics Global Ltd (NASDAQ:PRE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for PRE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for PRE spans 6-K, 4.

Recent high-impact activity:

  • Prenetics Plunges 38% to 52-Week Low as 2H EBITDA Loss Guidance Widens to $30M-$35M
  • Prenetics Q3 Revenue $64.1M Beats Guidance; 2H Adjusted EBITDA Loss Widened to $30-35M
  • Prenetics Posts $64.1M in Third-Quarter Revenue
  • Prenetics' IM8 Signs Diplo as Global Ambassador and Equity Shareholder
  • Prenetics Files Care Bears by IM8 License: 10-Year Term, GMRs, Royalties and ABG Equity Stake

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$92.39M
Net Income
-$39.98M
Diluted EPS
-$2.68
Op. Cash Flow
-$21.83M
Free Cash Flow
-$22.03M
Gross Profit
$48.79M
Operating Income
-$44.48M
Cash & Equivalents
$32.13M
Debt / Equity
0.00×
Net Margin
-43.3%
Source: 20-F · filed 2026-04-30 · accession 0001628280-26-028623

Short Interest & Short Volume

2.83 days to cover

FINRA reported short interest of 507,416 shares in PRE as of the October 30, 2026 settlement, a 1.5% decrease from the prior period — about 2.8 days to cover at its recent average daily volume. On November 20, 2026, 41.6% of PRE volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)507,416 shares as of October 30, 2026
Change vs prior period▼ 1.5%
Days to cover2.83 at avg daily volume of 179,606
Daily short volume (FINRA facilities)41.6% of 216,380 shares on November 20, 2026
5-day average short volume57.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for PRE, detected from its recent SEC filings.

1 shelf registration

Auditor Consents Filed · Unregistered Securities Disclosed

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

PRE files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with P →
$8.97 +1.93% today
52-week range · as of 2026-11-18 $8.97 – $27.24
Market cap
$149.05M
Volume
596.4K (2.3× avg)
3-mo avg 257.9K
Live data · 2026-11-21 15:02 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PRE - Latest Insights

PRE
Nov 18, 2026, 12:40 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.17
Real-time Price: $8.97 info
Change: -$1.19 (-12%) info
Market Cap: $149.052M info
PRE
Nov 18, 2026, 8:06 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $17.83
Real-time Price: $8.97 info
Change: -$8.86 (-50%) info
Market Cap: $149.052M info
PRE
Nov 18, 2026, 8:05 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $17.83
Real-time Price: $8.97 info
Change: -$8.86 (-50%) info
Market Cap: $149.052M info
PRE
Nov 17, 2026, 10:35 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $16.09
Real-time Price: $8.97 info
Change: -$7.12 (-44%) info
Market Cap: $149.052M info
PRE
Nov 05, 2026, 8:53 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $16.20
Real-time Price: $8.97 info
Change: -$7.23 (-45%) info
Market Cap: $149.052M info
PRE
Nov 05, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $16.20
Real-time Price: $8.97 info
Change: -$7.23 (-45%) info
Market Cap: $149.052M info
PRE
Nov 02, 2026, 9:13 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $18.23
Real-time Price: $8.97 info
Change: -$9.26 (-51%) info
Market Cap: $149.052M info
PRE
Oct 13, 2026, 6:53 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $21.16
Real-time Price: $8.97 info
Change: -$12.19 (-58%) info
Market Cap: $149.052M info
PRE
Aug 26, 2026, 8:23 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $22.17
Real-time Price: $8.97 info
Change: -$13.20 (-60%) info
Market Cap: $149.052M info
PRE
Aug 24, 2026, 9:41 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $21.82
Real-time Price: $8.97 info
Change: -$12.85 (-59%) info
Market Cap: $149.052M info
PRE
Aug 20, 2026, 10:32 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $18.76
Real-time Price: $8.97 info
Change: -$9.78 (-52%) info
Market Cap: $149.052M info
PRE
Aug 18, 2026, 7:40 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $19.99
Real-time Price: $8.97 info
Change: -$11.02 (-55%) info
Market Cap: $149.052M info
PRE
Aug 18, 2026, 7:33 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $19.45
Real-time Price: $8.97 info
Change: -$10.48 (-54%) info
Market Cap: $149.052M info
PRE
Aug 07, 2026, 8:51 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $19.00
Real-time Price: $8.97 info
Change: -$10.03 (-53%) info
Market Cap: $149.052M info
PRE
Jul 14, 2026, 1:35 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $20.43
Real-time Price: $8.97 info
Change: -$11.46 (-56%) info
Market Cap: $149.052M info
PRE
Jul 14, 2026, 1:25 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $18.55
Real-time Price: $8.97 info
Change: -$9.58 (-52%) info
Market Cap: $149.052M info
PRE
Jun 10, 2026, 12:51 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $19.02
Real-time Price: $8.97 info
Change: -$10.05 (-53%) info
Market Cap: $149.052M info
PRE
Jun 10, 2026, 8:37 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $20.00
Real-time Price: $8.97 info
Change: -$11.03 (-55%) info
Market Cap: $149.052M info
PRE
Jun 10, 2026, 8:31 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $20.93
Real-time Price: $8.97 info
Change: -$11.96 (-57%) info
Market Cap: $149.052M info
PRE
Jun 04, 2026, 8:32 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $20.55
Real-time Price: $8.97 info
Change: -$11.58 (-56%) info
Market Cap: $149.052M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets